

<u>ANNEX</u>: PIH COVID-19 Annex provides a space for job aids tools and quick references for staff to use in implementing a response to the COVID-19 pandemic. All documents here correspond directly to the Official PIH Guides and are organized accordingly. These will be frequently updated to correspond directly to the official guidelines.

# **Data Collection Tools**

- 1. Contact tracing and Community-based Care
- 2. Intake, Symptoms Screening, Exposure, and Outcomes
- 3. Lab Orders and Test Results
- 4. Facility-based care

# Cleaning and Disinfecting

- 1 Acceptable Disinfectants
- 2 Cleaning and Disinfecting Guidelines
- 3 Cleaning Clinical Spaces
- 4 Cleaning Non Clinical Spaces
- 5 COVID19 Transport guidelines
- 6 Liquid Chlorine Preparation

# **PPE** Guidelines

- 1 PPE conservation
- 2 PIH guide to extended use and reuse of masks and eye protection
- 3 Extended Use PPE donning and doffing
- 4 PIH Covid Nonstandard PPE Memo

# Facilities and Infrastructure

1. PHI BHI Covid Response

# COVID-19 Data Collection Tools Overview

# Introduction

Based on analysis of WHO tools and other clinical frameworks, we have prepared data collection forms and registers for paper, Excel, and use with CommCare, and OpenMRS. These tools are a guide to help your team identify the data that could be collected, and map out your own workflows for data sharing and data use.

Even while specific forms & tools may vary by country, we aim to establish a common core of key performance indicators that will be powerful tools to inform PIH's care delivery, advocacy, and fundraising.

These tools are not finalized documents, they are sample materials for planning. We expect sites and facilities will adapt these via translations and other changes to meet your team's needs. We hope to have your feedback on these options and improve them collaboratively.

Word and Excel documents are provided in the PIH COVID 19 Sharepoint folder. For CommCare and OpenMRS options, please contact <a href="mailto:BostonSIS@pih.org">BostonSIS@pih.org</a> and we can help get these tools set up for you. Note that additional options for REDCap and other tools are under investigation and consideration, and our Boston team can also help connect you with relevant experts.

# Click on the form areas below to be taken to form descriptions:

- 1. Contact Tracing and Community-based Care
  - A. Contact Tracing and Isolation Monitoring Register
  - B. Case Monitoring in Community Register
  - C. Suspected Case Testing Follow-Up Register
- 2. Intake, Symptoms Screening, Exposure, and Outcomes
  - A. Intake and Symptom Screening for Cases or Contacts
  - B. Exposure and Final Outcomes for Cases or Contacts
- 3. <u>Lab Orders and Test Results</u>
  - A. Rapid Test Request and Result Form
  - B. Lab Register
- 4. Facility-based care
  - A. Facility Patient Register
  - B. Facility Admission Form
  - C. Facility Daily Progress Form
  - D. Facility Discharge Form

# 1. Contact Tracing and Community Monitoring Registers

Find editable versions here.

# A. Contact Tracing and Isolation Monitoring Register

	0 0
What	A register to collect a COVID-19 case's recent contacts. This register allows any contact tracer to find and screen contacts. The register also allows contact tracer to follow up with contacts to monitor for symptom development, refer for testing, and close out contact record at the end of isolation period or upon conversion to a case.
Where	List of contacts can be filled in facility if case is admitted or in community if case is at home/isolation facility. Contact follow up happens in community wherever contact is.
Who	Contact Tracer
When	When a COVID-19 case gives a list of their contacts, then it is maintained at any follow up with contacts

# B. Case Monitoring in Community Register

What	A register or patients who are positive but have mild symptoms and are isolating
	at home/isolation facility. Health workers will need to monitor these people for
	worsening symptoms and support home-based care.
Where	Community, either at home or an isolation facility where the case is.
Who	Any care team member following up with community-based cases of COVID-19
When	A new person is added to a team member's list when they become responsible for
	monitoring a case in the community.

# C. Suspected Case Testing Follow-Up Register

What	A register for people who are still waiting for confirmatory testing and may not be COVID-19 cases despite symptoms or exposure. Suspected cases move off this list quickly when their diagnosis is presumed, confirmed or ruled-out at the end of the isolation time period.
Where	First filled at the laboratory where patient receives first rapid test. Intended for
	tracking at community level, but could be adapted for follow up of admitted
	patients who are also awaiting <b>confirmatory</b> test results.
Who	Community care team member who is assigned to follow up with patients who
	need confirmatory testing
When	When a symptomatic person requires confirmatory testing to determine diagnosis.
	Suspect is assigned to a community care team member, and moved from the list
	when it is determined that patient will be isolating in community, or admitted to
	facility, or is not a COVID-19 case.

# **COVID-19 Contact Tracing and Isolation Follow Up List**

Case ID:	Case Name:	Case phone number:
Case Address:	Nearest health facility:	Date of interview :/
Data Collector name:	Data Collector phone:	<b>Location of interview:</b> ☐ Facility ☐ Community

Line	Assigned Contact ID	Phone Number	Age	Date of Last Contact with	Scheduled Date of	Date Symptoms	Referred for testing	Assigned Case ID <sup>1</sup>	Final Outcome <sup>2</sup>
No.	Name of Contact	Address of Contact (Town/Village and Landmarks)			Isolation End (DD/MM/YY)	Develop (DD/MM/YY)	and results		Outcome
				, , ,	,	· · · · · · · · · · · · · · · · · · ·	□ refer		
1			□M □F	/ /	/ /	/ /	_ +		
							□ refer		
2			□M □F	/ /	/ /	/ /	_ <b>+</b>		
							□ refer		
3			□M □F	/ /	/ /	/ /	_ +		
							□ refer		
4			□M □F	/ /	/ /	/ /	_ <b>+</b>		
							□ refer		
5			□M □F	/ /	/ /	/ /	_ +		
							□ refer		
6			□M □F	/ /	/ /	/ /	_ <b>+</b>		
							□ refer		
7			□M □F	/ /	/ /	/ /	_ <b>+</b>		
							□ refer		
8			□M □F	/ /	/ /	/ /	_ <b>+</b>		
							□ refer		
9			□M □F	/ /	/ /	/ /	_ +		

1Received on positive test result or presumed positive.

<sup>&</sup>lt;sup>2</sup>NS=Never had symptoms REC=recovered RF=refuse D=died L=Lost A=admitted



**COVID-19 Case Community Monitoring List** 

P	a	g	e	#
-		o	_	

Data collector name:	Location:	Date (dd/mm/yyyy):

Line	Case Name Assigned Case ID	Address of contact (Town/Village &Landmark) OR (Location of isolation)	Sex	Date of Symptom Onset	Date of Scheduled Isolation End	Develop Severe Symptoms?	Still symptomatic at end of Isolation?	Final Outcome <sup>1</sup> (See
Number	Assigned Contact ID (if case started as a contact)	Phone Number	Age	(DD/MM/YY)	(DD/MM/YY)	Refer to health facility?	If Yes → New Date of Isolation End	
1			□ M □ F	/ /	/ /	□ severe □ refer	□ still symptom / /	
2			□ <b>M</b> □ F	/ /	/ /	□ severe □ refer	□ still symptom / /	
3			□ M □ F	/ /	/ /	□ severe □ refer	□ still symptom / /	
4			□ <b>M</b> □ F	/ /	/ /	□ severe □ refer	□ still symptom / /	
5			□ M □ F	/ /	/ /	□ severe □ refer	□ still symptom / /	
6			□ M □ F	/ /	/ /	□ severe □ refer	□ still symptom / /	
7			□ <b>M</b> □ F	/ /	/ /	□ severe □ refer	□ still symptom / /	
8			□ M □ F	/ /	/ /	□ severe □ refer	□ still symptom / /	

<sup>&</sup>lt;sup>1</sup>REC=Recovered D=Died RF=Refuse Follow up L=Lost A=Admitted



# **COVID-19 Suspected Case List (for patients who need confirmatory testing)**

Name of date collector	Location of data collector	

#	Date of initial diagnostic test (DD/MM/YY)		Age	Address of Suspected Case (Town/Village and Landmarks)	Test	Scheduled Date of Second Rapid Test (+5 days from first) OR	Results of Second Rapid Test or Confirmatory Test	Suspected Case Next Steps <sup>1</sup> (See codes below)
					(DD/MM/YY)	Actual Date of PCR Confirmatory Test (DD/MM/YY)		
1					/ /	□ 2 <sup>nd</sup> RDT □PCR	□ <b>+</b> □ -	
2					/ /	□ 2 <sup>nd</sup> RDT □PCR	- -	
3					/ /	□ 2 <sup>nd</sup> RDT □PCR	_ + 	
4					/ /	□ 2 <sup>nd</sup> RDT □PCR	- -	
5					/ /	□ 2 <sup>nd</sup> RDT □PCR	- + -	
6					/ /	□ 2 <sup>nd</sup> RDT □PCR	- + -	
7					/ /	□ 2 <sup>nd</sup> RDT □PCR	- + -	
8					/ /	□ 2 <sup>nd</sup> RDT □PCR	- + -	
9					/ /	□ 2 <sup>nd</sup> RDT □PCR	- + -	
10					/ /	□ 2 <sup>nd</sup> RDT □PCR	- + -	
11					/ /	□ 2 <sup>nd</sup> RDT □PCR	□ <b>+</b>	
12					/ /	□ 2 <sup>nd</sup> RDT □PCR	□ <b>+</b>	
13					/ /	□ 2 <sup>nd</sup> RDT □PCR	□ <b>+</b>	
14					/ /	□ 2 <sup>nd</sup> RDT □PCR	_ + 	

<sup>1</sup>Next Step Codes :RF=Case refuses follow up; N=Follow up not necessary; A=Admitted; L=Lost; M=Move case information to Case Community Monitoring List



# 2. Intake, Symptoms Screening, Exposure, and Outcomes

# Find editable version here.

Note: these forms are combined into one document. If printed front and back the forms are combined into the below:

# A. Intake and Symptom Screening for Cases or Contacts

What	<ul> <li>Demographics and Conditions (front of form):</li> </ul>							
	<ul> <li>Demographic information</li> </ul>							
	<ul> <li>Maternal, neonatal and child health information</li> </ul>							
	<ul> <li>Pre-existing conditions</li> </ul>							
	Symptom screening (back of form):							
	<ul> <li>History of illness and fever</li> </ul>							
	<ul> <li>Danger signs</li> </ul>							
	<ul> <li>Other symptoms</li> </ul>							
Where	Facility screening or Community. Stays with facility staff if patient is admitted to facility,							
	community health worker if patient is isolating at home or in an isolation facility, or with							
	patient if there is not community follow up available.							
Who	Facility or Community frontline worker							
When	Once – at first interaction with individual							

# B. Exposure and Final Outcomes for Cases or Contacts

What	Exposure (front of form):
	<ul> <li>General COVID-19 exposure information (travel, occupation, contact with known case)</li> </ul>
	<ul> <li>Contact with COVID-19 case information</li> </ul>
	Final Outcomes (back of form):
	<ul> <li>Defines final outcomes for Cases (COVID-19 cases). Note: that discharge from a facility while the patient is not yet recovered is not a final outcome. Follow up will be required to get final outcome of these patients.</li> </ul>
	<ul> <li>Defines final outcome for Contacts (those who had contact with confirmed cases, but never were confirmed or presumed to be positive).</li> <li>Note: final outcome for Contacts includes being converted to a Case if Contact receives a confirmed or presumed COVID-19 diagnosis, a case outcome will be required for these people.</li> </ul>
Where	Facility or Community. Stays with facility staff if patient is admitted to facility, community
	health worker if patient is isolating at home or in an isolation facility, or with patient if
	there is not community follow up available.
Who	Facility or Community frontline worker
When	Exposure is taken once at first interaction with individual. Final Outcomes is filled when a patient has a final outcome in either the facility or the community.

# **COVID-19 Patient Intake and Symptoms Screening**

1. Patient Status at Intake ☐ Con	firmed case ☐ Presumed case ☐ Contact							
1.1 Case ID (if COVID-suspected or -confirmed):								
1.2 Contact ID (if close contact of COVID case):								
*a person may have a contact and case ID if they started as a contact and then were converted to a case								
2. Contact Information and Demograph	nics							
2.1 First name:	2.2 Surname:							
2.3 Sex: ☐ Male ☐ Female	2.4 Date of Birth: / (DD/MM/YYY)							
2.5 Age:YearsMonths	2.6 Nearest Health Centre							
2.7 Telephone number	2.8 National social number/ identifier							
2.9 Other Electronic Number (HIV ID/NCD ID/EMR ID)	2.10 Community Health Worker Name							
2.11 Province/Region if non-national, list country here	2.12 District/Commune							
2.13 Town or Village	2.14 Landmark/street name							
3. Visit Information	[pre-print country here]							
<b>3.1 Facility Name</b> list community if not in facility	3.3 Date of interview // (DD/MM/YYY)							
3.2 Data collector name	3.4 Data collector phone number							
4. Symptoms								
4.1 Has the respondent experienced any respirator symptoms (cough, shortness of breath, sore throat running nose) in the last 14 days?	·							
4.2 Fever (≥38 °C) or history of fever	$\Box$ No $\Box$ Yes → Start date:/							
4.3 Dry cough	$\square$ No $\square$ Yes $\rightarrow$ Start date:/							
5. Danger Signs								
5.1 Rapid Breathing or Shortness of Breath	$\Box$ No $\Box$ Yes → Start date:/(DD/MM/YYYY)							
5.2 Altered consciousness	$\square$ No $\square$ Yes $\rightarrow$ Start date:/							
5.3 Inability to eat, drink, or walk	□ No $□$ Yes $→$ Start date:/(DD/MM/YYYY)							
If yes to at least one danger sign, patie	nt needs to be seen by clinician immediately							



# **COVID-19 Other Symptoms and Pre-existing Conditions**

6. Other symptoms	Check all that	apply					
□ Sore throat	□ Runny n	ose	If Yes to any $ ightarrow$				
□ Chest pain	□ Loss of a	ppetite	Start date for first symptom:				
☐ Muscle aches (Myalgias)	□ Neurolo	gical signs	// (DD/MM/YYYY)				
☐ Fatigue or general malai	se 🗆 Seizures		, , ,				
□ Vomiting or Nausea	□ Rash						
□ Diarrhoea	□ Conjunc	tivitis					
□ Headache	□ Other sy	□ Other symptoms, specify:					
7. Pre-existing Cond	ition(s) check all	that apply					
☐ Obesity		☐ Chronic lun	ng disease (non-asthma)				
☐ Underweight		☐ Chronic live	er disease				
☐ Hypertension			gical disorder/Sickle cell disease				
☐ Diabetes Type 1		☐ Chronic kid	ney disease				
☐ Diabetes Type 2		☐ Epilepsy					
□ HIV			urological impairment/disease				
☐ TB		☐ Cancer					
☐ Heart disease	lication)	☐ Stroke					
<ul><li>☐ Asthma (requiring med</li><li>☐ Mental health condition</li></ul>	•	<ul><li>☐ Other immune deficiency</li><li>☐ Other pre-existing condition:</li></ul>					
			existing condition.				
		☐ Current					
7.2 Smoking		☐ Former					
		□ Never					
	1 . 40	□ No	Date: / /				
7.3 Vaccinated for influen	za last 12 months	$\square$ Yes $\rightarrow$	Date: / (DD/MM/YYYY)				
		□ Unknown	(55),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
7.4 Received pneumococo	eal vaccino	□ No	Date:/				
7.4 Received pheumococc	ai vaccine	<ul><li>☐ Yes →</li><li>☐ Unknown</li></ul>	(DD/MM/YYYY)				
			<u> </u>				
8. Maternal and Chil		ation					
	$\square$ No $\square$ Yes $\rightarrow$ Trimesto	er: 🗆 First 🗀 Se	cond □ Third □ Unknown				
8.1 Pregnant	,	ed delivery date:					
	□ Unknown		(DD/MM/YYYY)				
8.2 Post-partum	□ No						
Delivery in last 6 months	,	date:/	<u>/</u>				
,	☐ Unknown	(טט) וויוי	<u>, ,                                   </u>				
8.3 Is patient <1 year old?	YES → <b>Breastfeedi</b>	ng?	□ Yes □ No				
6.5 is patient <1 year old:	TES → <b>Dieastieeui</b>	ng:	□ Unknown				
			□ Yes				
8.4 Is patient <5 years old?	YES → <b>Are vaccinati</b>	ons up to date?	□ No				
			□ Unknown				



# **COVID-19 Patient Exposure Screening Form**

1. Patient Status	G □ Conf	irmed case 🗆	☐ Presumed case ☐ Contact							
1.1 Case ID (if COVID	-suspected or -confirmed):									
1.2 Contact ID (if clos	se contact of COVID case):									
*a person may have a conta	act and case ID if they started as a	contact and then we	ere converted to a case							
2. Contact Inform	nation and Demograp	hics (fill if sepa	rated from intake form)							
2.1 First name:		2.2 Surname:								
2.3 Telephone number		2.4 National soci	al number/ identifier							
2.5 Province/Region		2.6 District/Com	mune							
2.7 Town or Village		2.8 Landmark/st	reet name							
3. General Expos	ure Information	•								
-	d within the last 14 days? egions and Cities visited:	□ Yes → □ No □ Unknown	☐ Domestically ☐ Internationally  Start date: / / / (DD/MM/YYYY)  End date: / / / (DD/MM/YYYY)							
3.2 Have you been pro in the last 14 days?	esent in a healthcare facilit	y ☐ Yes → ☐ No ☐ Unknown	Facility:							
3.3 Occupation	<ul><li>☐ Health worker</li><li>☐ Health laboratory w</li><li>☐ Student</li><li>☐ Other, specify:</li></ul>	vorker	If YES to any → location of work or study:							
	s, have you had contact wit d or confirmed COVID-19	$\square$ No $\rightarrow$ Go	o to Primary Case Contact Information to Symptoms Form Go to Symptoms Form							
•	Contact Information had contact with a known/sus	posted COVID 10 C	200							
5.1 Name of primary CO		•	primary COVID-19 case							
5.3 Relationship to prim	ary COVID-19 case	5.4 Date of las / (DD/MM/YYY)	t contact with case							
5.5 Does contact	No were spent were spe	within 6 ft of case	e							
	number of r	esidents in the ho	Jille							



# **COVID-19 Patient Follow Up Form**

1. Patient Status ☐ Confirmed case ☐ Presumed case ☐ Contact							
1.1 Case ID (if COVID-suspected or confirmed):							
1.2 Contact ID (if close contact of COVID case):							
*a person may have a contact and case ID if	f they started as a contact and then were converted to a case						
3. Close CONTACT Record							
Complete if respondent had contact wi	th a known/suspected COVID-19 Case						
	<ul> <li>Completed isolation period without becoming a confirmed or presumed COVID-19 case</li> </ul>						
3.1 What was contact outcome?	☐ Lost to follow up						
	☐ Died						
	☐ Refused follow up						
	☐ Became a confirmed or presumed COVID-19 case						
	→ Go to Close CASE Record						
4. Close CASE Record							
Complete if respondent was a known/s	uspected COVID-19 Case						
	☐ Recovered outside health facility (isolation period ended)						
	☐ Recovered at health facility (discharged)						
4 4 14/h at	☐ Lost to follow up						
4.1 What was case outcome?	□ Died						
	☐ Transferred out (Facility name:)						
	☐ Refused treatment or follow up						



# 3. Lab Orders and Test Results

# Find editable versions here.

# A. Rapid Test Request and Result Form

What	Submit orders and specimens to lab for testing
	Record test results
Where	At screening location and in laboratory. Stays with facility staff if patient is admitted to facility, community health worker if patient is isolating at home or in
	an isolation facility, or with patient if there is not community follow up available.
Who	Orders: Completed by Clinical staff
	Results: Completed by Clinical or Laboratory Staff
When	When tests are ordered and completed

# B. Lab Register

What	Record basic patient information in one row per patient to easily tally number of each kind of test performed and the results				
Where	In laboratory. Stays in laboratory.				
Who	Clinical or Laboratory Staff				
When	When tests are ordered and completed				



CommCare option available



OpenMRS lab order and entry

Date:		
Jaic.		

# **COVID-19 Test Register**

Facility	v Name:	

			R	ease	on			1st Rapid Test			2st Rapid Test (if							Date of PCR Test	DC	R Te	act.					
	Patient Name	Age	Sy	Е		Date of 1st	Ar	ntibod		st	Ant	igen '	Test	Date of 2nd	An	tibody		t		gen T	est	(if applicable)			251	
Case ID	Contact Info	Sex	Symptoms	Exposure	Contact	Rapid Test	IgG Positive	IgM Positive	Negative	Invalid	Positive	Negative	Invalid	Rapid Test (if applicable)	IgG Positive	IgM Positive	Negative	Invalid	Positive	Negative	Invalid	Sample ID	Positive	Negative	Invalid	Notes
		□M□F	S	Ex	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M □F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	_	NV			IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		1	1																							
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	
		□M□F	S	NV	С		IgG +	IgM+	(-)	inv	(+)	(-)	inv		IgG +	IgM+	(-)	inv	(+)	(-)	inv		(+)	(-)	inv	



# **COVID-19 TEST REQUEST FORM**

1.Patient Status at Intake								
1.1 Case ID (if COVID suspected):								
1.2 Contact ID (if close contact of COVI	D case):							
*a person may have a contact and case ID if they started as a contact and then were converted to a case								
2. Contact Information and Demographics								
2.1 First name:		2.2 Surname:						
<b>2.3 Sex:</b> □ Male □ Female		2.4 Date of Birth:						
<b>2.5 Age:</b> Years(if <60 mont	IVIOITUIS	2.6 Telephone number						
Check if patient is a health worker:								
3. Request Information		[pr	re-print country here]					
3.1 Facility Name		3.2 Date of request	•					
2.2.Time of tests.	4/1~C\	2.4 Time of specime	(DD/MM/YYY)					
3.3 Type of test: ☐ Antibody test (IgN☐ Antigen test	/I/IgG)	3.4 Type of specime	n: ☐ Nasai swab☐ Oropharyngeal swab☐					
□ RT PCR test			☐ Venous blood					
□ NI FCN test			☐ Finger prick (blood)					
3.5 Additional info/Comment:			☐ Filiger prick (blood)					
3.3 Additional may comment.								
3.6 Requested by:		3.7 Signature:						
т.	o he comp	leted in the labora	atory					
4. Specimen/Sample Information		eteu III tile labora	atory					
4.1 Sample ID:		2 Collected by:						
4.1 Sample ID.	7.4	Collected by.						
4.3 Sample Collection Date and Time:		:						
	(DD/MM/YYY)	HH:MM						
5. Test Information								
5.1 Test Performed by:	5.2 Test Date	and Time:/						
		(DD/MM/YYY	· •					
5.3 Result Antibody test:	5.4 Result Ar	ntigen test:	5.5 Result RT PCR test:					
☐ Negative	☐ Negative		☐ Negative					
☐ Positive IgM only	$\square$ Positive		☐ Positive					
☐ Positive IgG only	If result is in	valid re-do test	☐ Invalid					
☐ Positive IgM and IgG								
If result is invalid re-do test								
3.5 Additional info/Comment:								
	<del></del>		T					
Result communicated to:	Date of resul	It://	Signature:					



# 4. Facility-based care for COVID-19 Cases

Find editable versions <u>here</u>. Editable versions of the Facility Admission, Daily Progress, and Discharge forms require a program called Balsamiq (email <u>BostonSIS@pih.org</u> for more information).

# A. Facility Patient Register

What	Monitors the overall situation in the wards as a way to understand the status of currently and historically admitted cases. Collects information about admission date, basic demographics, COVID-19 and secondary diagnoses, intensive care needed, medications and outcomes
Where	Filled in facility ward. Stays in facility.
Who	Clinical staff
When	Patient information is entered on admission. Staff maintains register throughout treatment receives a <b>facility</b> outcome. (Facility outcome may not be a patient's final outcome if they are discharged before recovery.)

# B. Facility Admission Form

What	Based on WHO Core Case Record form - collects information at admission like symptoms, medications, secondary diagnoses
Where	Filled in facility ward. Stays in facility unless patient is discharged to recover in home/isolation facility, then forms transfer with patient to a community health worker, or isolation facility staff. If there is no community health worker or isolation facility staff available then forms should stay in facility.
Who	Clinical staff
When	Filled upon admission to health facility

# C. Facility Daily Progress Form

What	Based on WHO Core Case Record form – daily assessment of vitals and lab results
	and admission to intensive care
Where	Filled in facility ward. Stays in facility unless patient is discharged to recover in
	home/isolation facility, then forms transfer with patient to a community health
	worker, or isolation facility staff. If there is no community health worker or
	isolation facility staff available then forms should stay in facility.
Who	Clinical Staff
When	Filled daily for any number of days admitted to the facility

# D. Facility Discharge Form

What	Based on WHO Core Case Record form – discharge information for patients upon leaving the facility, includes secondary diagnoses and medications given to patient upon discharge
Where	Filled in facility ward. Stays in facility unless patient is discharged to recover in home/isolation facility, then forms transfer with patient to a community health worker, or isolation facility staff. If there is no community health worker or isolation facility staff available then forms should stay in facility.
Who	Clinical Staff
When	Filled at time of discharge from facility

Date:				COVI	ID-1	.9 Patie	nt T	reat	men	t Ro	egis	ter		Facility N	ame:			
				COVID-19	A	ICU Start	Int	ensive		_	/ledic	atio	ns			Outcome		
Date of Admission	Case ID	Patient Name	0 -	Suspected or Confirmed	mit Tit	D-4-		Noni Ven	lno Vaso	Chlo	Hyo chlo	Ant	Anti	Discharge Date	Outcome Date	(see	Transfer	Notes
D/M/Y	r delene ivanic	I NOV	Secondary Diagnosis	Admit to ICU	ICU End Date	vygen erapy	Noninvasive Ventilation Oxygen Therapy	Chloroquine Inotrope/ Vasopresser	Hydroxy- chloroquine	Antivirals	Antibiotics	D/M/Y	D/M/Y	codes below)	Out Facility	Hotes		
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	CQ	HCQ	AV	AB					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	CQ	HCQ	AV	AB					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	CQ	HCQ	AV	AB					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	CQ	HCQ	AV	AB					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	cq	HCQ	AV	AB					
	Ţ			□ susp □ conf														_
			□M□F				ОТ	NV	IN/VA	cq	HCQ	AV	АВ					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	CQ	HCQ	AV	AB					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	cq	HCQ	AV	AB					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	cq	HCQ	AV	АВ					
				□ susp □ conf														
l			□M□F				ОТ	NV	IN/VA	CQ	HCQ	AV	AB					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	cq	HCQ	AV	АВ					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	cq	HCQ	AV	АВ					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	cq	HCQ	AV	АВ					
				□ susp □ conf														
			□M□F				ОТ	NV	IN/VA	cq	HCQ	AV	АВ					
OUTCOM	E CODES:				-	-												
REC=Reco	overed at fa	acility and dischar	rged, <b>ISO</b> =[	Discharged to	o Iso	lation/u	nwel	l <b>l,</b>										
TO=Trans	fer Out, <b>RI</b>	E <b>F</b> =Refused Care,	<b>D</b> =Died															



Partners In Health 2-April-2020

page 1 of 2

Patient Name:

Age:

Patient Id:

EMR Id:

# **Admission Note**

Date:	Time:		Sex:				Hospital day #	<b>‡:</b>
Patient Demographics			Patient	<b>History</b> syr	nptom sta	rt date:		
Employed as Healthcare Wo	orker Yes N	No	Fever			Chest pain		
Patient is pregnant?	Yes N	No	Cough		_	Muscles ache	es (Myalgias)	
Gestational Age:	weeks			ım production		Fatigue/mala		
Or Expected Due Date:				of breath (Dyspne		Nausea/vomi		
Doct navtum nationt?		do.	Sore throa	t		Diarrhea		
Post-partum patient?			Runny nos	e		Loss of taste/	/smell	
Outcome: I live birth still b	irth Delivery Date:		Headache			Confusion		
Patient is Infant?  Gestational Outcome:   Breastfeed:   Yes  No	☐ Yes ☐ N erm birth (≥37wk GA) ☐ Preterm birth		Other, spe	ecify:				
If child, vaccinations up to c	date? □ Yes □ No		Vitals					
– Home Medications ––––			Temp	°C °F	Cap refil	I time	3 sec	
			Pulse	bpm			sec	
– Allergies –			RR	bpm	Pain:	None	Mild	
· ·			BP	/ mmHg		Moderate	Severe	
			02	% on	_L/min	ro	om air	
Comorbidities	e Unknown		Physical	l Exam				
Type 1 Diabetes	Chronic kidney disease		AVPU	Alert	☐ Verba	l Pain	Unresponsive	
Type 2 Diabetes	Asthma		System	Normal		Findi	ngs	
Hypertension	Chronic pulmonary diseas (not asthma)	se 🔘	HEENT	Yes (	No			
Epilepsy	Tuberculosis		Neck	Yes (	No No			
Sickle Cell disease	Cardiomyopathy		Lungs	Yes (	No			
Rheumatic Heart Disease	Stroke		Thorax	Yes (	No			
HIV	Malnutrition		Heart	Yes (	No			
Mental Health Condition:			Abdomen	Yes (	No			
Smoking: Current F	Past Never		Urogenital		No No			
Other:			Back		□No			
			Skin		_No			
Onset/Admission			Musculosk		No No			
Transfer from other facility?	Yes N	lo	Other, spe		No			
-	Admission Date: _		ourer, spe	<i>,</i> .				
Known contact with COVID- in 14 days prior to sympton		lo						

# **Admission Note**

# **COVID-19 Testing**

Name \_\_\_\_\_

Specime	n Date	9	Specimen Ty	/pe		Tes	t <sup>-</sup>	Туре	Test Result				
/_	//		☐ Nasal swab ☐ Oropharyngeal swab ☐ Venous blood ☐ Finger prick (blood)		0	☐ Antibody test (IgM/IgG) ☐ Antigen test ☐ RT PCR test			☐ Nega☐ Nega☐ Nega	alid tive	Positive Ig Positive Ig Positive Ig Positive	G only	alid /
//			☐ Nasal swab ☐ Oropharyngeal swab ☐ Venous blood			☐ Antibody test (IgM/IgG) ☐ Antigen test			_	ative ilid	Positive Ig Positive Ig Positive Ig Positive Ig	M only G only	gG
//			☐ Finger prick ☐ Nasal swab ☐ Oropharyng ☐ Venous bloo ☐ Finger prick	eal swab d		☐ RT PCR test ☐ Antibody test (IgM/IgG) ☐ Antigen test ☐ RT PCR test			Nega Nega Inva Nega Nega	ative llid tive	Positive Ig Positive Ig Positive Ig Positive Ig Positive Ig Positive	G only	gG ⁄alid
Other test	ing												
Test	result		Test	result			Г						
Haemoglobin	g/	/L or /dL	Sodium		mmol/L			Thest X-Ray performed? Result:	' U	Ultra Resu	sound perfori ilt:	med?	
Haematocrit		96	Potassium		mEq/L								
WBC count		09/L or 03/μL	BUN		mmol/L o mg/dL								
Lymphocyte count	ce	lls/µL	Creatinine		µmol/L or mg/dL		L	241		041-			
Neutrophil count		lls/µL 09/L or	Glucose		mmol/L or mg/dL µmol/L or			Other diagnostic tests:		Otne	er findings:		
Platelets	x1	03/µL nol/L or	Total Bilirubin		mg/dL	-							
Lactate	mg	g/dL	ALT/SGPT		U/L								
CRP		ng/L	AST/SGOT		U/L								
Chloroquin  Second Line  Lopinavir/r  Remdesivi	oroquine 400mg PO ne phosphate 500m <b>Medications</b> — itonavir 400mg/100m	mg PO bid	for 10 days h x 14 days				) (	ortive Care  Oxygen Um  Paracetamol mg  der Clinical Plan —	in IV I	ho	our		ml/hour
Ceftriaxone	2 gm q hou	irs 🔲	Amoxicillin	q hours		Nu	rsi	ing Admission Note					
Doxycycline	2 100 mg BID												
_ Diagnosis _													
COVID-19: Confirmed Suspected No						ture:							
Secondary/Oth	er Diagnoses:							Admit to ward Discharge to:	Discharg	e to h	ome isolation		

Signature

Partners In Health 2-April-2020

Partners In Health 2		Jres.	s Note		Patient Nar	ne:				Patient ld:
Dai	iy i i o	51 C3.	3 NOCE		Age:					EMR Id:
Date:		Time	e:		Sex:					Hospital day #:
Patient His	story				Vitals					
Symptom		new	0		Temp	0,	C °F	Cap refi	II time	☐ < 3 sec
Fever		<u> </u>		unchanged   worsened	Pulse		bpm	cup ren	ii diiic	sec
Cough		U			RR		bpm	Pain:	☐ None	☐ Mild
With sputum p		U		unchanged worsened	BP	/	mmHg	raiii.	☐ Mode	
Shortness of b	reath (Dyspnea	) [		unchanged   worsened	02	0/	6 on	L/min		7 room air
Sore throat				unchanged worsened				_ [///////		J
Runny nose		U			Physic	ai Exa	ım			
Chest pain	(0.4:1)	- U		unchanged worsened	AVPU		Alert	☐ Verba	al 🗌 Pai	n Unresponsive
Muscles aches		<u> </u>		unchanged worsened	Syste	m	Normal		F	indings
Fatigue/malais		U		unchanged   worsened	HEENT		Yes (	_No		
Nausea/vomiti	ng			unchanged worsened	Neck			No		
Diarrhea		U		unchanged   worsened	Lungs		0	_No		
Confusion				unchanged   worsened	Thorax			_]No		
Loss of taste/sr			U improved	anchanged   Worsened	Heart			No No		
Other, specify:					Abdome			No		
Testing (si	nce last no	ote)			Urogenit	al	0	No No		
Test	result		Test	result	Back			]No		
Haemoglobin		g/L or g/dL	Sodium	mmol/L	Skin			_No		
Haematocrit		96	Potassium	mEq/L	Musculo	skeletal		□No		
WBC count		x109/L or x103/µL	BUN	mmol/L or mg/dL			☐Yes 〔	No		
Lymphocyte		cells/µL	Creatinine	μmol/L or	Other, sp	ecity:				
count Neutrophil		cells/µL	Glucose	mg/dL mmol/L or	-					
count		x109/L or		mg/dL µmol/L or	First L	ine Me	dications –			
Platelets		x103/µL mmol/L or	Total Bilirubin	mg/dL	Hyd	roxychlo	roquine 400m	g PO q12h x	24 hours then	200mg q12h for 5-10 days
Lactate		mg/dL	ALT/SGPT	U/L	Chlo	oroquine	e phosphate	500mg PO bi	id for 10 days	
CRP		mg/L	AST/SGOT	U/L	Secon	d Line I	Medication	s ———		
Chest X-Ray pe	rformed?		Ultrasound per Result:	formed?			onavir 400mg/	100mg PO q1	2h x 14 days	
Result:			Result.		Ren					
SARS-CoV-2 Ar	ntibody RDT	SARS-Co	V-2 Antigen	SARS-CoV-2 RT-PCR	Antibi				)	H
Negative Ab		☐ Negar		Negative			gm q 100 mg BID	hours	Amoxicili	linq hours
Positive IgM o		☐ Positi		☐ Positive ☐ Invalid						
Positive IgG+	lgM				Other	Medica	ations ——			
☐ Invalid Other diagnost	ic tests:		Other findings:		-					
					_Suppo	rtive Ca	are			
										ml/hc
Primary Dia	gnoses:						nol m			
COVID-19:	Confirm	ned 🗌	Suspected [	No						
Other:					Provid	er Clini	ical Plan —			
Secondary [	Diagnoses:				]					
Pneumonia	Jiugiioses.		Congestive hea	rt failure	1					
Acute Respirat	ory		Myocarditis		1					
Distress Syndr			Acute renal inju	urv/ O	-					
			Acute renal fail	ure U						
Anemia Meningitis/			Liver dysfunction  Hyperglycemia		Nursin	g Progi	ress Note –			
Encephalitis			пурегдусенна		-					
Seizure			Hypoglycemia		1					
Dehydration			Cardiac arrest							
Other:					Signatu	ıre:				

Provider Name: \_\_\_\_\_ Signature \_\_\_\_\_

Partners In Health 2-April-2020

Name \_\_\_\_\_

Disch	arge N	Mote	P	atient Name:	Patient Id:	
Disch	arger	AOLE	<i>A</i>	ige:	EMR Id:	
Date:	Tim	ne:	2	ex:	Hospital day #:	
Primary Diagnoses:						
	ontirmed C	Suspected No No		Therapy given during h	_	
Other:	Jilli Illea [	J Suspected   140			Oxygen Therapy? Yes N	
				Non-invasive ventilation?		
Secondary Diagnose	es:			Inotrop	es/vasopressors?  Yes  N	VO.
Viral pneumonia		Congestive heart failure	)		Antibiotics? Yes	Vo
Bacterial pneumonia		Myocarditis	)	Other intervention of Pro	ocedure.	
Acute Respiratory Distress Syndrome		Acute renal injury/ Acute renal failure	)	other intervention of the	occurre.	
Pleural effusion		Liver dysfunction	)			
Anemia		Hyperglycemia	)`	- Discharge Information	1	
Meningitis/ Encephalitis		Hypoglycemia	)			
Seizure		Cardiac arrest	)	Discharge Date:	_/	
Other:				Disposition:		
ICII/Isolation				Discharged		
ICU/Isolation ICU or High Depen				Continued home iso	olation: Yes No	
	Total dura	tion in ICU:		Transfer to other fa	acility	
				☐ Death		
	date of ICI	J admission//		Other (specify):		
	date of ICI	J discharge//		Discharge condition:	☐ Good/recovered	
Dischause Madiestie				3	Fair	
					Poor	
Chloroquine phosp		x 24 hours then 200mg q12h for 5-10 days				
		bid for to days		Follow up plan:		
Amoxicillin						
Doxycycline 100 mg B						
Other Antibiotic: _						
Coricosteroids: Typ	pe	Route Dose		Other comments:		
Antifungal agent						
Paracetamol	_ mg every_	hour				
Other medications:						

Signature \_\_\_\_\_

Patient Name:



<u>Introduction</u>: Below describes PIH's approach to Cleaning and Disinfecting throughout the COVID-19 pandemic. Please do not hesitate to reach out with questions to the <u>COVID-19@pih.org</u>

- 1 Cleaning and Disinfecting Guidelines
- 2 Cleaning Clinical Spaces
- 3 Cleaning Non Clinical Spaces
- 4 COVID19 Transport guidelines
- 5 Acceptable Disinfectants
- 6 Liquid Chlorine Preparation (English and French)

# Cleaning and Disinfecting Guidelines

- 1. Prepare
  - Don disposable gloves
  - Close off areas to be cleaned
  - Wait as long as practical before beginning cleaning and disinfection
  - Open outside doors and windows
- 2. **Clean** (Clean surfaces using a detergent or soap and water **before** disinfection)
  - Remove visible pollutants (blood, secretions, excreta)
  - Damp mopping is better than dry mopping
  - Wash Surfaces that have come into direct human contact or are frequently touched
  - Sterilize all cleaning materials used
- 3. **Disinfect** 
  - Prepare Solution using Acceptable Disinfectant guidelines
  - Wipe the area with the disinfectant solution using a cloth
  - Start with cleaner regions first, and contaminated regions after
  - Dispose or sterilize cloth immediately after use
  - Doff disposable gloves immediately after disposing cloth
  - Perform hang hygiene using soap and water. (If water is unavailable, clean hands with alcohol-based hand rub)



# Cleaning Clinical Areas Including Isolation units: COVID-19 Cleaning and Disinfection Instructions

Type of Surface	Examples	Soap and Water	Disinfect
	Floors	When Dirty. At least 3 times/ week.	After Human Contact /When Dirty. At least
Minimally Touched Surfaces	Ceilings		weekly.
	Walls		
	Windows		
Frequently Touched Surfaces	Door Handles, Table Tops / Desks, Light Switches , Computers , Sinks/Basins	Daily	Daily

I DISPOSAL OF EXCEPTA	Conduct hand hygiene, treat feces as biohazard, disposed in separate toilet/latrine for suspected or confirmed cases of COVID-19, clean bedpan with neutral detergent &water, disinfected with a 1% chlorine or 0.5% sodium hypo-chlorite solution
Laundry	Place soiled linen placed in leak-proof bags/containers, removing solid excrement to be disposed of in a toilet/latrine. Machine washing recommended (warm water at 60–90° C with laundry detergent)  • If machine washing not possible, soak linens in hot water and soap in a large drum using a stick to stir > soak linens in 1% chlorine for approximately 30 minutes> rinse laundry with clean water> dry fully in sunlight



# **Cleaning Non-Clinical Spaces**

Type of Surface	Examples	Soap and Water	Disinfect	
	Floors			
Minimally Touched	Ceilings	3 times daily + any known COVID-	3 times daily + any known COVID-	
Surfaces	Walls	exposure	exposure	
	Blinds			
	Door Handles			
	Table Tops / Desks		3 times daily	
Frequently Touched	Light Switches	3 times daily +between each patient	+between each  patient	
Surfaces	Computers		patient	
	Sinks/Basins			

# **COVID-19 Transport Guidelines**

Updated: 24 March 2020

# 1. General Hygiene Guidelines for Drivers and Transport Staff

- a. If possible, wear new disposable gloves for every journey
- b. If not wearing gloves: Before, during, and after each trip, wash your hands with soap and water for at least 20 seconds. Use an alcohol-based hand sanitizer that contains at least 60 percent alcohol if soap and water are not available.
- c. Avoid touching your face, eyes, nose, or mouth with unwashed hands.
- d. Avoid close contact with passengers
- e. If possible, ask passengers to sit in the back to create physical distance.
- f. Have hand sanitizer available for both driver and passengers
- g. Please reference JOB AID Rwanda Evac for evacuating positive patients to treatment centers

# 2. Vehicle Disinfection

- a. Routine Cleaning/Disinfection Before and After each trip and at the end of each shift/day
  - 1. Use a 70% alcohol-based solution (or soap and water if not available) to wipe down all high-touch surfaces: steering wheel, shifter, door handles, windows, any other area that has been touched by passengers or driver
  - 2. Deep cleaning After each trip carrying symptomatic patients, follow routine cleaning plus: Full cleaning of all passenger areas, including: floor, passenger seat, back of front seat, door, window, etc.
- b. If proper cleaning/disinfection cannot be performed, leave vehicle unused for minimum 48 hours

# Recommended Minimum Cleaning and Disinfecting Frequencies

Type of Surface	Examples	Soap and Water	Disinfect
Minimally Touched	Exterior, Headliner, Trunk	When Dirty	Only after Human
Surfaces			Contact
Frequently Touched	Door Handles, Switches,	Routinely	High Touch Areas
Surfaces	Dashboard, Carpet, Seats		
	Steering		
	Wheel, Shifter, Keys, Interior		
	Windows		

Choosing the Right Disinfectant (please see below for acceptable disinfectants)

- Use an Alcohol-based cleaner for cars.
- Avoid: Chlorine Bleach as it can damage plastic, fabric and metal
- DO NOT MIX SOLUTIONS



# a. Trip Guidelines

Low-Risk Trips	Medium-Risk Trips	High-Risk Trips
Low-Risk Trips  As many carriers of COVID-19 are asymptomatic, the only no-risk journey is by yourself.  a. PPE (Mask and Gloves) Recommendations: follow general hygiene guidelines  b. Follow routine cleaning instructions above  c. Maximum capacity: 1 (driver only)	Medium-Risk Trips  Non-medical trips, including carrying asymptomatic close contacts, Medical trips carrying patients with other conditions (trauma, obstetric), No high-risk passengers (pre-existing health conditions, elderly, etc.)  b. PPE (Mask and Gloves) Recommendations  a. Masks and gloves highly recommended for passengers and driver  b. Follow routine cleaning instructions above.  c. Maximum Capacity: 4  d. Keep windows open during trip	Symptomatic patients, Patients in high-risk categories (pre-existing health conditions, elderly, etc.) Symptomatic and high-risk passengers should only travel for purposes of medical treatment  d. PPE (Mask and Gloves) Recommendations: Masks and gloves must be worn by all occupants in the vehicle e. For moving patients, wear appropriate full PPE, including eye protection, gown and gloves f. After helping a medical passenger out of the car, you should remove all protective equipment and wash your hands or use hand sanitizer before getting back into your vehicle. g. Follow routine and deep cleaning instructions above h. Maximum Capacity:4 i. Keep windows open



# **Acceptable Disinfectants**

Disinfecting Solution	Concentration	Directions	Use on	Do NOT use on
Diluted chlorinebleach (5.25% sodiumhypochlorite)	0.5% (1:50)	Apply, leave for 10 min,rinse	Floors, desks, non- porous surfaces	Computers, phones, screens, fabric, can discolor plastic, metal
Chlorine	.5%	Apply, leave for 10 min,rinse	Floors, desks, non- porous surfaces	Computers, phones, screens, fabric, can discolor plastic, metal
Hydrogen Peroxide	0.5%	Apply	Floors, desks, non- porous surfaces, metal	Fabric
Ethanol / EthylAlcohol	62% minimum	Apply	Computers, Phones, Non- porous surfaces	Can discolor plastic
Isopropyl Alcohol	70% minimum	Apply	Computers, Phones, Non- porous surfaces	Can discolor plastic
Propanol	70% minimum	Apply	Computers, Phones, Non- porous surfaces	Can discolor plastic

Do NOT use: Ammonia, vinegar Do NOT: mix multiple disinfectants

Preparation and use of disinfectant solution

- Gloves should be worn when handling and preparing bleach solutions.
- Protective eye wear should be worn in case of splashing.
- Cleaning solutions) should be made up daily.
- Leave the disinfectant solution on the surface for a sufficient time is required to kill the virus − 1 minute for alcohol based cleaners
- No rinsing needed with alcohol based cleaners



# **Liquid Chlorine Preparation**

English Version – Updated 23 March 2020

	Liquid Chlorine Preparation					
	% Solution	0,05 %	0,05 % 0,5 %			
	Use for:	Hands, skin, laundry, clothes	Floors, walls, equipment	Disinfection of stool, vomit, blood. Disinfection of corpses.		
Basic Product	Bleach, 5% sodium hypochlorite (5 % active chlorine)	10 milliliters in 10 liters of water	1 liter in 10 liters of water	4 liters in 6 liters of water		
	Chlorine laundry powder (30% active chlorine)	16 grams (1 tablespoon) in 10 liters of water	16 grams (1 tablespoon) in 1 liter of water	64 grams (4 tablespoons) in 1 liter of water		
	Chlore en granules (HTH) (70 % de chlore actif)	8 grams (1/2 tablespoon) in 10 liters of water	8 grams (1/2 tablespoon) in 1 liter of water	32 grams (2 tablespoons) in 1 liter of water		

ALWAYS label solutions using an permanent marker

Note: WaterGuard is 1.25% Sodium Hypochlorite --> if this is used, then will need to use different ratios



# **Liquid Chlorine Preparation**

Version française – Mis à jour 23 March 2020

	Préparation de solution chlorée						
	Solution de:	0,05 %	0,5 %	2 %			
	Utilisé pour:	Mains, peau, linge, vêtemen ts		Gestion de selles et vomissement s (désinfectées dans des seaux), Désinfection de cadavres			
Produit d e base	JIF, Klowoks liquide (5 % de chlore actif)	10 millilitres dans 10 litres d'eau*	1 litre dans 10 litres d'eau*	4 litres dans 6 litres d'eau			
	Klowoks en poudre pour blanchissment de veteme nts (30 % de chlore actif)	1 cuillère à soupe (16 grammes) dans 10 litres d'eau*	1 cuillère à soupe (16 grammes) dans 1 litre d'eau	4 cuillères à soupe (64 grammes) dans 1 litre d'eau			
	Chlore en granules (HTH) (70 % de chlore actif)	1/2 cuillère à soupe (7 grammes) dans 10 litres d'eau*	1/2 cuillère à soupe (7 grammes) dans 1 litre d'eau	2 cuillères à soupe (28 grammes) dans 1 litre d'eau			

ALWAYS label solutions using an permanent marker

Note: WaterGuard is 1.25% Sodium Hypochlorite --> if this is used, then will need to use different ratios



Annex: PPE Guidelines | Updated 3 April 2020

<u>Introduction</u>: Below describes PIH's approach to PPE usage throughout the COVID-19 pandemic. Please do not hesitate to reach out with questions to the COVID-19@pih.org

- 1. PPE conservation
- 2. Extended use and reuse of masks and eye protection
- 3. Extended Use PPE donning and doffing
- 4. Nonstandard PPE Memo

# PIH Guide to PPE Conservation

Our priority is the safety of our patients and healthcare workers. It is **CRITICAL** that as triage and isolation systems are rapidly planned and implemented, early efforts are made to **conserve PPE** as global stock is limited. Conserving PPE now will ensure enough supplies to keep providers safe throughout the pandemic

# Strategically Reduce Individual PPE Use

- Extend Use & Re-Use: Extended use is preferred over reuse. Extended use of respiratory protection is defined as the wearing of a disposable mask without removal or re-donning of the mask. Due to the rapidly evolving epidemic and to ensure protection for the frontline health workers many organizations, including the CDC is recommending re-use when necessary. See below for safe re-use procedures.
- Concentrate Care Delivery: Develop Strategies to complete multiple task utilizing the same set of PPE. For example: taking vital signs and giving medication at the same time.
- Appropriate use of PPE: WHO recommends the use of a surgical mask for the routine care of suspected COVID patients, and the use of N95 in COIVD patients during aerosolizing procedures like intubation or nebulization. When able N95 masks should be replaced after any aerosolizing procedure however, re-use of N95 masks may be necessary. N95 masks should be used according to PIH protocols for TB treatment

# Reuse PPE:

*Face Shields:* Reusable face shields can be soaked in sodium hypochlorite 0.5% for 1 hour and left in a clean, open space to dry for at least 1 hour

**Gowns:** In some wards, gowns may need to be worn continuously as a provider moves between patients. In these cases, the provider should double glove and change outer gloves between patients. If gowns are in short supply, re-usable gowns can be considered. (see PIH guidelines on alternative PPE). If reusable gowns are used they should be machine washed with 60-90° C water and laundry detergent

Surgical and Procedural Masks: Given current supply global levels, most hospitals will need extended use of masks between patients (meaning that the mask is not removed between patients but stays on a provider's face continuously). At many hospitals, masks will need to be re-



Annex: PPE Guidelines | Updated 3 April 2020

used (meaning removed from the face and then put back on in between patients). PIH has a job aid to assist with safe re-use of mask. Key tenants of this include:

- Surgical and procedural masks must be worn by a single wearer.
- The removed mask should be placed in a designated receptacle for reuse.
- Perform hand hygiene immediately before and after putting on or otherwise touching a reused mask.
- Masks must be replaced when dirty or contaminated

Our priority is the safety of our patients and healthcare workers. It is **CRITICAL** that as triage and isolation systems are rapidly planned and implemented, early efforts are made to **conserve**PPE as stock is limited globally. Conserving PPE now will ensure enough supplies to keep providers safe throughout the epidemic – how to safely conserve and re-use PPE?

# Minimize Number of People using PPE

- On Patient Rounds: Consider only having direct caregivers interact with the patient rather than members of the team responsible for the care of other patients
- On Shift: Designate a subset of caregivers to operate in the isolation area, rather than more providers in both areas. All caregivers can adhere to the above strategies to reduce PPE usage
- In the Operating Room: Limit surgeries to only essential surgeries and limit the number of observes and non-essential personnel, reducing the number of PPE sets used.
- In General: No visitors for patients suspected or confirmed to have COVID-19 (with the exception of parents for children). Visitors cannot enter COVID-19 isolation ward.

# Role for hospital administrators:

Hospital administration should actively enforce PPE conservation measures. Some strategies used include:

- Removing or limiting PPE on wards less likely to require them
- Centralized PPE distribution instead of PPE stored on wards
- PPE monitors who can correct individuals when PPE is overused (for example, if an N95 mask is used in a situation where a surgical mask would have been sufficient)



# PIH guide to extended use and reuse of masks and eye protection

During the COVID pandemic, extended use (when the mask or eye protection is worn continuously and not taken off between patients) or reuse (when the mask or eye protection is removed and then replaced) of personal protective equipment may be required.

# In general:

- *Keep your mask on continuously as much as possible!* Extended use is preferred over reuse because there is less risk of spreading the virus.
- You can never do hand hygiene enough! Remember hand hygiene before and after removing or replacing any PPE item
- If you need to take your mask off, take it all the way off. For example, do not pull a mask down under your chin to take a drink of water. This keeps your face from being accidently contaminated by the outside of the mask.

## How to remove a mask:

- Perform hand hygiene
- Remove mask carefully by the straps. Do not touch the outside surface (dirty surface).
- Place the mask in your designated storage container ensure you always place the dirty side (the outside of the mask) in the same direction
- Perform hand hygiene

# How to put a used mask back on:

- Perform hand hygiene and put on gloves
- Carefully pick the mask up by the straps, and ensuring the outside does not touch your nose or mouth, replace it on your face
- Remove gloves and perform hand hygiene
- Only re-use your own mask

# When to replace a mask for a new one:

- If it is wet or dirty
- If it is damaged
- If it has been used in an aerosol generating procedure, such as intubation, nebulization, or suctioning (for N95s)

# When do I need an N95 instead of a surgical mask:

• When swabbing a patient for a COVID test (extended use or reuse ok)



Annex: PPE Guidelines | Updated 3 April 2020

• When performing an aerosol generating procedure, such as intubation, nebulization, or suctioning (discard after the procedure)

# How to remove and reuse eye protection:

- Remove eye protection by the handles of the goggles or strap of the face shield. Carefully place outside down (dirty side down) in a 'dirty bin.'
- Perform hand hygiene. Then either:
  - o Option 1: Put on new gloves. Clean all sides of the eye protection with the cleaning solution. Place the eye protection into your own designated storage container (separate from your mask), dirty side (outside down). Remove gloves and perform hand hygiene.
  - o Option 2: Reusable eye protection may be soaked in sodium hypochlorite 0.5% for 1 hour and left in a clean, open space to dry for at least 1 hour.

# Extended Use PPE — Donning Stop Martners OPENEDATION Updated 27 March 2020

1. Don PPE outside of patients room. Ensure hair is pulled back away from face.



Alcohol-based sanitizer OR soap and water







Ensure gown fully covers entire body when closed or tied







- If new mask/respirator, hold mask/respirator in one hand and bring to face
- Pull lower elastic band over head and below ears
- Pull upper elastic band over head and above ears Press nose clip to ensure a tight seal of mask
  - If re-using mask/respirator, hold by straps only, taking care not to touch the outside (dirty) side of the mask





Alcohol based hand sanitizer

















Ensure gloves go over cuff of gown

6. Put on gloves

put 2 pairs of gloves on. Change external If using same gown between patients, pair between each patient



Annex: PPE Guidelines | Updated 3 April 2020

# Extended Use PPE — Doffing Stop Mariners OPENEDATRICS

face shield, front of gown and sleeves are CONTAMINATED. Wash hands immediately 1. Doff PPE, except for mask/respirator in patient's room/ward. Remember gloves, if you touch any of these surfaces with your bare hands


- 2. Remove gown
- Avoid touching outside contaminated surface of gown
- Pull gown from head and away from body
- If possible, remove gloves at same time as gown, ensuring you only touch the inside of gown and gloves
- Wrap gown into a ball with contaminated surface (outside of gown) inside
  - Discard gown in appropriate receptacle







Alcohol-based hand sanitizer



- Grasp gloves in palm of hand and pull glove off
  - Discard glove in waste container
- Slowly and gently slide finger under other glove between glove and cuff of gown.









Updated 27 March 2020





- 6. Remove eye protection
- Alcohol-based hand sanitizer
- If using face shield, tilt head forward, grasp strap and gently pull strap over head, pulling the face shield away from face
  - Carefully place outside down (dirty side down) in a 'dirty bin' until they can be cleaned If using googles, grasp ear pieces behind ears and pull googles and away from face
    - for re-use (see instructions on re-using PPE)



7. Perform hand hygiene





- 8. With mask/respirator in place, leave patients room and enter anteroom or hallway
- 9. Remove mask/respirator
- Pull lower elastic band over head
- If re-using, place mask/respirator in an appropriate storage container (plastic container Pull upper elastic band over head and pull mask away from face recommended). Ensure dirty side of mask/respirator is face down











Alcohol-based hand sanitizer



# Guidance on Non-Standard PPE for COVID-19

The global COVID-19 pandemic has led to worldwide shortages of personal protective equipment (PPE). This document discusses alternative non-standard PPE that can be considered. It is important to note that, at present, none of the options below have sufficient evidence to recommend their routine use. First steps to expand PPE availability should be PPE conservation which includes extended use, re-use, and limiting the number of people and procedures that would require PPE. Please see PPE conservation guidance.

The use of non-standard PPE should be used as a 'last resort' strategy. The strategies below are unproven and their ability to protect a healthcare worker is unknown.

# Non-standard Mask Options

- Locally made cloth masks
  - Should be worn with face shield that extends to the chin or below for added protection
  - To increase effectiveness, masks should be made with tightly-woven, fluid-resistant fabric and fit closely to the face, over both the nose and mouth
  - Effectiveness may decrease when wet; should be replaced if sweaty or damp
  - It should be noted multiple studies show these do not provide as much protection as official surgical masks and they should only be worn as last resort. One study suggests an increased infection risk and a false sense of protection for clinicians.
  - During this time of global shortage there are some institutions that are prioritizing the use of cloth masks in low-risk areas to conserve the use of surgical masks and N95s to higher risk and known risk patient areas.
- Makeshift 'respirators' from surgical masks and viral filters are being researched as alternate N95s in aerosolizing procedures
  - o <a href="https://www.childrenshospital.org/research/departments-divisions-programs/departments/surgery/surgical-innovation-fellowship">https://www.childrenshospital.org/research/departments-divisions-programs/departments/surgery/surgical-innovation-fellowship</a>
- Multiple organizations are researching options to sterilize single use masks, but no standards have emerged yet. More information on this may be available in coming weeks.


# Non-standard gown options


- Locally made gowns can be considered in the absence of certified gowns. There is limited data on these.
  - Should be made of cloth with small pore size: non-woven, spun bound fabric, or tightly-woven, fluid-resistant fabric (such as polyester)
  - Certified re-usable gowns are typically coated with a fluorocarbon-based repellant finish to prevent liquid and microbial penetration. This may not be possible with local gowns, so particular care should be taken to avoid getting gowns wet and to change when wet.
  - Design:



Annex: PPE Guidelines | Updated 3 April 2020

- Extends to knees; fully covers arms and torso (front as one piece and back with ties)
- Cuffs at end of arms (consider thumb loops to prevent gap between gown and gloves)
- Higher neck to protect against splashes
- Tight-seams or sealed seems
- Inspect with each use to ensure no visible holes
- Clothes worn underneath a locally made gown should be inspected after doffing –
  if soiled, they must be properly sterilized or discarded
- Other gown alternatives include lab coats, patient gowns, aprons, combinations of clothing (sleeve covers + coats) and should be used as a last resort.






1 CONFIRMED WARD - EQUIPMENT SCALE 1:100







PRESUMPTIVE WARD - EQUIPMENT SCALE 1:100



1 CONFIRMED WARD - DIM + TAGS
SCALE 1:100








PRESUMPTIVE WARD - DIM + TAGS

SCALE 1: 100


SK03 FLOOR PLAN D&P



PRESUMPTIVE WARD

SCALE 1: 100


1 CONFIRMED WARD
SCALE 1:100












### 1 PRESUMPTIVE WARD





2 CONFIRMED WARD
SCALE 1:50













# 1 CONFIRMED WARD NORTH SCALE 1: 100

2 CONFIRMED WARD EAST SCALE 1:100






3 CONFIRMED WARD SOUTH SCALE 1: 100

4 CONFIRMED WARD WEST SCALE 1: 100











METAL ROOF 0.451 m 1 - 6" 0.914 m 3' - 0" 0.914 m 1/2" CDX PLYWOOD 1.374 m 4' - 6" 1.219 m 4' - 0" 1.219 m 1.829 m OR 7/16" OSB SHEATHING CONCRETE FLOOR 18.288 m

## PRESUMPTIVE WARD NORTH SCALE 1:100

### **PRESUMPTIVE WARD EAST**

SCALE 1:100





# 3 PRESUMPTIVE WARD SOUTH SCALE 1:100


4 PRESUMPTIVE WARD WEST SCALE 1:100








CORRUGATED





1 3D AXON PRESUMPTIVE WARD SCALE

23D AXON CONFIRMED WARD








### -CORRUGATED METAL ROOFING -2X2 STEEL PURLINS PER STRUCTURAL DETAIL -INSULATION B/W PURLINS & METAL ROOFING DOUBLE TOP PLATE -STEEL TRUSS ROOF FRAME - SEE DETAIL -DOUBLE 2X4 HEADER -DOUBLE TOP PLATE CONT 6 MIL WHITE PLASTIC SHEET INTERIOR (TURN INTO WINDOW OPENING) CONT 6 MIL WHITE PLASTIC SHEET -STAPLE TO INTERIOR OF WALLS -ROLL-UP TARP NAILED AT TOP. SEE **ELEVATION DETAIL** SCREEN NAILED ONTO EXTERIOR WALL OF BUILDING 1/2" CDX PLYWOOD OR 7/16" OSB SHEATHING -1/2" CDX PLYWOOD OR 7/16" OSB SHEATHING -2X4 STUD WALL @ 24" OC 2X4 STUD WALL @ 24" OC CONT 6 MIL WHITE PLASTIC SHEET INTERIOR CONT 6 MIL WHITE PLASTIC SHEET **INTERIOR** EXPANDING CONCRETE ANCHOR ATTACHMENT 0,152 r EXPANDING CONCRETE ANCHOR ATTACHMENT 4" CONCRETE SLAB 4" CONCRETE SLAB FRAMED PLYWOOD WALLS





WINDOW COVERING ELEVATION




FRAMED PLYWOOD WALLS @ WINDOWS










**OPTION A: PLUMBED SINK** 




**OPTION B: BUCKET SINK** 









































# PENDING STRUCTURAL DESIGN









PRESUMPTIVE WARD TYPICAL POWER PLAN


CONFIRMED WARD TYPICAL POWER PLAN









SK-16





**LEGEND** 

**Draft- For Review** 



PRESUMPTIVE WARD

SCALE 1:100


**1** CONFIRMED WARD SCALE 1:100







SK-17









SK-18

Example of Electrical Distribution Plan

### Typical Ward Panel Schedule

	PROJECT: PIH COVID		PANEL	PP-1			_	٦
	LOCATION:	Presumptive Ward						
	VOLTAGE:	230	PH: 1	WIRE:	2 KAIC 10			
	MAIN BUS:	62 AMPS		NEUTRAL BUS: 100%				
	MAIN BREAKER:	32 A FRAME		62 A TRIP				
	MOUNTING:	Flush		GROUND BUS: FULL				
	TOTAL VA			FEEDER: COVID MDP				
						L1	)	Y
	DIRECTORY	L1	L2	CKT.	AMPS			
R	Clean Receptacles Bldg #2	720		1	10/1 RCBO		Œ	
R	Bed Receptacles Bldg #1		720	2	10/1 RCBO		Œ	
R	Bed Receptacles Bldg #1	720		3	10/1 RCBO		€	
R	Bed Receptacles Bldg #1		720	4	10/1 RCBO		Œ	
R	Bed Receptacles Bldg #1	720		5	10/1 RCBO		Œ	
R	Bed Receptacles Bldg #1		720	6	10/1		Œ	
L	Lights & Fans Bldg #1	916		7	10/1		Œ	
L	Spare		0	8	6/1		Œ	
Е	Spare	0		9	10/1		Œ	e
Е	Spare		0	10	12/1		Œ	
	SUBTOTAL	3,076	2,160					_
	RCPT: 1ST 10KVA @ 100% =		4,320	VA				
	Remaining KVA @ 50% =		0					
	LIGHTING: KVA @ 100% =			VA				
	EQUIP.: KVA @ 100% =		0	ı				
	TOTAL DEMAND =		5,236	ji				
	TOTAL AMPS		23.8	AMPS				

